Online inquiry

IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14254MR)

This product GTTS-WQ14254MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065
UniProt ID P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ14254MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10954MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ11975MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ7707MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ6308MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ2327MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ12803MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OMS721
GTTS-WQ11274MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI4893
GTTS-WQ6613MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DCDS0780A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW